Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear.
Vergouwen
Mervyn D I
MD
D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004146:Dioxanes / Q000494:pharmacology / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D023381:Endpoint Determination; D006801:Humans; D015201:Meta-Analysis as Topic; D017063:Outcome Assessment, Health Care; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000378:metabolism; D015203:Reproducibility of Results; D013345:Subarachnoid Hemorrhage / Q000150:complications*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D020301:Vasospasm, Intracranial / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology
D004146:Dioxanes; D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; D013777:Tetrazoles; C109641:clazosentan